Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
China
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
China
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
Although the Swine population represents the smallest of the market segments, Ceva is actively developing a swine portfolio to meet the requirements of the most prevalent sectors of this market.
Vaccines: Hyogen® (Mycoplasma hyopneumoniae), Circovac® (Circovirus Type 2)
Antibiotics: Tenaline® LA (Oxytetracycline), Florkem® (Florfenicol 300 mg/ml
Metabolism: Multivit Effervescent (Vitamin supplements)
Nutrients: Gleptosil® (Gleptoferron Iron supplement)
Coccidiostat: Forceris® (Gleptoferron and Toltrazuril combination)
Anti-microbial growth promoter: Ceva Olaquidox 10% (Olaquindox)
Last update: 03/03/2020
Back to top
